JNJ · News · 20261016N

Regulatory Approval Milestones

JOHNSON & JOHNSON · 2026-10-16 · Importance 30 · Surprise 42

An expert panel of the European Union drug regulator recommended six new medicines and five label expansions in October 2026. Johnson & Johnson was identified as one of the companies receiving a regulatory recommendation during the month. The recommendations could expand EU access to treatments for cancer and other conditions, although the report did not identify J&J’s specific medicine or quantify the potential financial impact.

Key facts

• Johnson & Johnson was cited as one of the companies that marked a regulatory win after an expert panel of the EU drug regulator recommended six new medicines and five label expansions for approval in October 2026. source